Association of different EGFR mutations with different outcomes in EGFR-mutated NSCLC patients treated with tyrosine kinase inhibitors. This is an ASCO Meeting Abstract from the 2016 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback